Table 1.
Characteristics of ALL survivor participants and nonparticipants
| Participants (n = 365) | Nonparticipants (n = 51) | P | |
|---|---|---|---|
| Age, median (range), y | 28.5 (18.4,44.6) | 27.3 (18.0-45.9) | .09 |
| Diagnosis age, median (range), y | 5.1 (0.6-18.8) | 4.6 (2.1-18.8) | .65 |
| Survival time, median (range), y | 21.9 (11.0-30.7) | 20.3 (11.3-27.8) | .11 |
| Sex | |||
| Male, n (%) | 174 (47.7) | 25 (49.0) | .89 |
| Female, n (%) | 191 (52.3) | 26 (51.0) | |
| Race | |||
| Black, n (%) | 44 (12.1) | 5 (9.8) | .89 |
| White, n (%) | 317 (86.8) | 46 (90.2) | |
| Other, n (%) | 4 (1.1) | 0 (0.0) | |
| Cranial radiation, n (%) | 149 (40.8) | 18 (35.3) | .13 |
| Glucocorticoids | |||
| Prednisone, n (%) | 365 (100.0) | 51 (100.0) | |
| Median (range), mg/m2 | 2240 (200-23 600) | 9650 (1120-11 800) | <.001 |
| Dexamethasone, n (%) | 75 (20.5) | 6 (11.7) | |
| Median (range), mg/m2 | 1568 (72-12 880) | 1568 (1400-1624) | .83 |
| IT hydrocortisone, n (%) | 291 (79.7) | 47 (92.2) | |
| Median (range) | 391 (18-105) | 369 (104 762) | .38 |
| Antimetabolites | |||
| IV methotrexate, n (%) | 320 (87.7) | 46 (90.2) | |
| Median (range), mg/m2 | 14 757 (449-40 571) | 13 424 (4753-25 683) | .89 |
| IT methotrexate (N,%) | 365 (100.0) | 51 (100.0) | |
| Median (range), mg | 156 (12-458) | 162 (80-336) | .62 |
| 6-Mercaptopurine, n (%) | 357 (97.8) | 51 (100.0) | |
| Median (range) mg/m2 | 47 250 (5994-130 900) | 47 250 (6185-74 900) | .48 |
| IT cytarabine, n (%) | 298 (81.6) | 48 (94.1) | |
| Median (range), mg/m2 | 576 (73-11 516) | 565 (108-1142) | .38 |
| Vincristine, n (%) | 365 (100.0) | 51 (100.0) | |
| Median (range), mg/m2 | 47 (3-105) | 54 (5-118) | .06 |
| Anthracyclines | |||
| Daunorubicin, n (%) | 242 (66.3) | 40 (78.4) | |
| Median (range) mg/m2 | 75 (24-451) | 87 (48-158) | .84 |
| Doxorubicin, n (%) | 40 (11.0) | 3 (5.9) | |
| Median (range), mg/m2 | 179 (25-324) | 169 (151-187) | 1.00 |
| Epipodophyllotoxins | |||
| Etoposide, n (%) | 223 (61.1) | 36 (70.6) | |
| Median (range), mg/m2 | 9462 (400-23 630) | 9978 (883-16 215) | .54 |
| Teniposide, n (%) | 220 (60.3) | 28 (54.9) | |
| Median (range), mg/m2 | 3241 (150-10 339) | 3478 (597-7983) | .84 |
| Asparaginase | |||
| L-asparaginase, n (%) | 361 (98.9) | 51 (100.0) | |
| Median (range), IU/m2 | 70 179 (4000-99 246) | 92 051 (40 308-347 783) | .01 |
| Erwinia, n (%) | 46 (12.9) | 5 (9.8) | |
| Median (range), IU/m2 | 54 980 (10 000-118 507) | 113 398 (20 000-247 083) | .42 |
IT, intrathecal.